IDH2突变抑制剂有Enasidenib(AG-221),中文名叫恩西地平(CSN17069),于2017年8月上市,用于治疗携带IDH2突变的复发性或难治性急性骨髓性白血病。 恩西地平的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。在接受最...
IDH2targetedmutationAMLIntroduction Mutations in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2, occur in approximately 20% of patients with acute myeloid leukemia (AML) and promote leukemogenesis through a block in normal myeloid differentiation and through the production of the oncometabolite ...
IDH2突变抑制剂有Enasidenib(AG-221),中文名叫恩西地平(CSN17069),于2017年8月上市,用于治疗携带IDH2突变的复发性或难治性急性骨髓性白血病。 恩西地平的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。在接受最短6个月的治疗后结果显示:大约19%的患者实现完全缓解,中位缓解持续期...
IDH2突变抑制剂有Enasidenib(AG-221),中文名叫恩西地平(CSN17069),于2017年8月上市,用于治疗携带IDH2突变的复发性或难治性急性骨髓性白血病。 恩西地平的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。在接受最短6个月的治疗后结果显示:大约19%的患者实现完全缓解,中位缓解持续期...
研究结果表明,虽然诊断AML时IDH基因突变的存在对HSCT巩固治疗的预后没有强烈的影响,但在HSCT时,较高的IDH1R132和IDH2R172基因突变MRD水平与复发风险增加相关。 参考文献: Marius Bill, Madlen Jentzsch, Lara Bischof, et al. Impact ...
Figure 2. IDH Mutation in Gliomagenesis View LargeDownload IDH mutation is thought to be an early if not the initial event in the development of low-grade astrocytomas and oligodendrogliomas. In support of this hypothesis, IDH mutation is found in secondary glioblastomas but not in primary glio...
13.Duchmann M, Micol J B, Duployez N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study[J]. Blood, 2021, 137(20): 2827-2837. 14.Han S, Liu Y, Cai S J, et al. IDH mutation in glioma: molecular mechanis...
1. IDH mutations incancer and progress toward development of targeted therapeutics; 2. Rigel announces US FDA approval of Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. News release. December 1, 2022...
et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 118, 409–412 (2011). Article CAS PubMed Google Scholar Xu, Q. et al. Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia...
1. IDH mutations incancer and progress toward development of targeted therapeutics; 2. Rigel announces US FDA approval of Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. News release. December 1, 2022...